Invests in
Sectors:
Locations:
Min Investment:
$301,116.00Max Investment:
$1,003,720.00Target Investment:
$652,418.00
Education
D.Phil
Lists including Peter
Work Experience
Co-Founder and CEO
2023
Every patient's cells have a longer story to tell
2022
Venture Partner (Techbio)
2022
Investing in the frontier of computer science and biology/chemistry Pre-seed to Seed | Tickets up to 1M Euros Peter[at]lunar.vc
2022 - 2022
Vice President Strategy
2022 - 2022
Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-a led biotech spinout from Oxford University, we empower the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high-efficiency vectors and intelligent clinical trial design.
2021 - 2021
Principal
2021 - 2021
On Investment Team. Deals included: Phenomic.AI (seed), Living Optics (seed), Kernal Biologics (pre-seed), Cytoseek (seed), Biomage (pre-seed, aquired) and Molecule One (seed).
2017 - 2021
Corporate Strategy Manager
2019 - 2021
Focus on digital tooling in bioprocessing, gene therapy, protein engineering and lab automation.
Business Development
2017 - 2019
2018 - 2021
Venture Partner
2018 - 2021
2016 - 2017
New Ventures Associate: Life-Sciences Ventures
2016 - 2017
Worked for a leading pharma company with a focus on therapeutic deal sourcing and evaluation
2014 - 2017
Chief Global Business Development Officer | Founding Member
2014 - 2017
2014 - 2015
CASE Placement (Discovery Biology)
2014 - 2015
2013 - 2014
Chapter President
2013 - 2014